Galectin Therapeutics

Galectin Therapeutics is a clinical‑stage biopharma developing belapectin (GR‑MD‑02), a galectin‑3 inhibitor in Phase II/III trials for liver fibrosis/NASH and multiple cancers, backed by an SBH‑owned joint venture.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 15
HQ: Norcross

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
GALT	Galectin Therapeutics Cap: 0.2B	EQUITY	NMS	USD	US3632252025	Active	📈